Text: H.R.5057 — 116th Congress (2019-2020)All Information (Except Text)

There is one version of the bill.

Text available as:

Shown Here:
Introduced in House (11/12/2019)


116th CONGRESS
1st Session
H. R. 5057


To clarify the treatment of pass-through status under the Medicare outpatient payment system for certain drugs.


IN THE HOUSE OF REPRESENTATIVES

November 12, 2019

Mr. Tonko (for himself and Mr. McKinley) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned


A BILL

To clarify the treatment of pass-through status under the Medicare outpatient payment system for certain drugs.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Pass-Through Technical Corrections Act”.

SEC. 2. Clarification of pass-through status under Medicare OPPS for certain drugs.

Notwithstanding section 1301 of the Consolidated Appropriations Act of 2018 (Public Law 115–141), in the case of a radiopharmaceutical drug for which pass-through status was provided pursuant to section 1833(t)(6) of the Social Security Act (42 U.S.C. 1395l(t)(6)) and whose period of pass-through status initially expired on either December 31, 2017, or December 31, 2018, if such radiopharmaceutical drug is indicated for positron emission tomography beta amyloid imaging covered under a coverage evidence development determination under section 1862(a)(1)(E) of the Social Security Act (42 U.S.C. 1395y(a)(1)(E)), then such pass-through status shall be extended until such date that the coverage with evidence development review is determined by the Centers for Medicare & Medicaid Services to be completed.


Share This